<DOC>
	<DOCNO>NCT02986321</DOCNO>
	<brief_summary>The purpose study evaluate dose-response relationship different dos CHF6001 identify optimal dose ( ) term benefit/risk ratio development target patient population .</brief_summary>
	<brief_title>A 24-wk Dose Ranging Study Evaluate Efficacy Safety 4 Doses New PDE4 Inhibitor Patients With COPD</brief_title>
	<detailed_description>This phase II , randomize , double-blind , double-dummy , placebo active control multinational , multicenter , dose ranging , 6-arm parallel-group study identify optimal dose CHF6001 , PDE4 inhibitor development , respect lung function symptom . After 2-wk run-in period formoterol ( Oxis Turbohaler® ) rescue salbutamol prn , patient randomize one 6 treatment group . After randomization , patient assess 3 , 6 , 12 , 18 24 week treatment clinic/hospital . A follow-up visit perform 12 day last visit . During study , patient report daily symptom EXACT-PRO/E-RS questionnaire , rescue/background medication use compliance study medication . AEs , SAEs COPD exacerbation monitor throughout study . At randomization subsequent visit , patient undergo physical vital sign examination , spirometry measurement , 12-lead ECG . Symptoms Health status assess validated questionnaire . Routine lab analysis blood biomarkers do .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
	<criteria>COPD patient Non childbearing potential woman permanently sterilize one highly effective contraception Current/ex smoker ( history &gt; 10 pack year ) Post bronchodilatator FEV1 &gt; =30 % &lt; =70 % predict normal value FEV1/FVC ratio &lt; 0.7 Documented history least 1 moderate severe exacerbation 12 month prior study entry Symptomatic patient ( MMRC score ≥2 CAT score ≥10 ) Patients daily maintenance therapy ICS/LABA . Diagnosis asthma respiratory disorder Maintenance bronchodilator therapy ( eg LABA alone ) Maintenance triple therapy . Occurrence moderate severe COPD exacerbation within 6 week prior study entry runin period . Patients require long term oxygen therapy . Concomitant recent pulmonary rehabilitation programme Known respiratory disorder COPD Lung cancer history lung cancer , active history cancer le 5 year disease free survival time Hypersensitivity β2agonist , corticosteroid , PDE4 inhibitors excipients Depression , generalise anxiety disorder , suicidal ideation Any clinically significant cardiovascular disease ( IM , CHF III/IV ; AF control therapy , etc ) within 1 year study entry Any relevant clinically significant cardiovascular condition , clinically abnormal significant 12lead ECG ( QTcF &gt; 450 m male &gt; 470 female ) clinically significant laboratory abnormality Serum potassium value ≤3.5 mEq/L &gt; 5.5mEq/L and/or fast serum glucose value ≥140 mg/dL . History symptoms significant neurological disease Unstable concurrent disease : eg uncontrolled Thyroid disease endocrine disease , gastrointestinal uncontrolled disease , uncontrolled immune diseases Renal impairment . Patients abnormal alanine aminotransferase and/ aspartate aminotransferase and/or bilirubin Current chronic history liver disease , know hepatic biliary abnormality patient receive treatment drug know well define potential hepatotoxicity Study entry Severely obese ( BMI ≥35 kg/m2 ) experience excessive weight loss recently History alcohol abuse and/or substance/drug abuse within 12 month prior screen visit . Any recent participation clinical Study investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>anti-inflammatory respiratory drug</keyword>
	<keyword>PDE4 inhibitor</keyword>
</DOC>